LLY — Eli Lilly and Company
Price when we picked it (Jul 23, 2026)
$1146.62
Target: $1236.00 (+7.8%)
P/E Ratio
40.7
P/E Forward
25.6
Dividend
0.54%
Market Cap
$1057.5B
EPS
$28.14
Consensus
Buy
What they do
Eli Lilly (NYSE: LLY) is one of the largest and oldest drug companies in the world, founded in Indianapolis in 1876. Today its growth engine is a single family of medicines —the so-called incretins or GLP-1— that copy a body hormone to reduce appetite and control blood sugar.
The star products:
- Mounjaro (tirzepatide, injection) — for type 2 diabetes. In Q1 2026 it brought in $8.66 billion (+125%), and for the first time it sells more outside the U.S. than inside.
- Zepbound (the same tirzepatide) — approved for obesity and sleep apnea. U.S. sales of $4.16 billion (+80%) in the quarter.
- Foundayo (orforglipron) — the new jewel: the first pill of the GLP-1 type for losing weight, approved by the FDA on April 1, 2026. Until now these medicines only came as an injection; a pill is much easier to make and to take (with no food or water restrictions), and it opens the door to hundreds of millions of new patients.
- Kisunla (donanemab) — for early Alzheimer's: it clears the plaques in the brain. Just starting to take off.
- Verzenio (breast cancer), Taltz (psoriasis), Jardiance (diabetes/heart, with Boehringer), and a lineup of younger launches (Ebglyss for eczema, Omvoh, Jaypirca).
Why it's booming now: obesity is the biggest drug market ever opened —hundreds of millions of people—, and Lilly arrived with the most powerful medicine and now also with the first pill. It controls close to 60% of the world market for GLP-1.
Leadership: CEO David A. Ricks (since January 2017, also chairman of the board). Headquarters in Indianapolis, Indiana. ~50,000 employees. In 2026 the company turns 150 years old.
Why we like it
LLY at $1,146.62 is buying the undisputed leader of the biggest wave in modern medicine, during a bout of profit-taking with no bad news behind it. Concrete reasons:
- Growth that almost no company its size achieves. In Q1 2026 (reported on April 30) it brought in $19.8 billion, +56%, with adjusted earnings per share rising +156%. And it raised its full-year target to $82-85 billion in revenue —more than 40% above 2025—.
- Market dominance. Its two versions of tirzepatide (Mounjaro + Zepbound) brought in $12.8 billion in a single quarter (~$51 billion a year). Lilly has ~60% of the global GLP-1 market.
- The pill changes everything. Foundayo, the first GLP-1 pill for losing weight, was approved on April 1. A pill is cheaper to produce and reaches far more people than an injection: it is the next step up in an already huge market.
- Its rival just stumbled. Novo Nordisk's rival medicine (CagriSema) lost a head-to-head comparison against Zepbound (20% vs 24% weight loss), and Novo projects that its obesity sales will shrink in 2026 while Lilly raises its target.
- It's cheaper than it looks. It trades at ~26 times expected earnings for a company growing +40% —one of the most reasonable valuations it has had in years—, and we bought it ~8% below its all-time high of $1,249, touched on July 7. 'Buy' rating, average target ~$1,236 (UBS sees $1,425). It reports on August 5: a near-term catalyst.
Key Risk
Risks:
- Sky-high valuation and expectations — the #1: at ~$1.06 trillion in market value and ~41 times historical earnings, the price already assumes flawless execution; the average target (~$1,236) sits just ~8% higher, and a single stumble in the August 5 report gets punished hard.
- Competition: Novo Nordisk is fighting for the market and has already started a price war —Lilly's real prices fell ~13% in the quarter—; further out, Amgen and Viking arrive with their own medicines (first launches ~2027).
- Government price pressure: the U.S. is forcing lower prices (a deal puts Mounjaro/Zepbound at ~$245/month for Medicare), and some of its medicines have already entered Medicare's mandatory price negotiation.
- Patent expirations: although tirzepatide is protected until ~2036, other medicines (Trulicity, Jardiance, Verzenio) lose protection this decade and that revenue has to be replaced —which is why Lilly keeps buying companies nonstop (it just paid up to $3.8 billion for AtaiBeckley)—.
- One business, one bet: much of the value depends on tirzepatide; a safety, manufacturing or regulatory problem in that family would hit very hard.
This is educational and informational content, not financial advice. Always consult a qualified financial advisor before making investment decisions.
Vectorial Data picked LLY on Jul 23, 2026 at $1146.62.
Full Research
Eli Lilly (LLY) — Full Research
Price: $1,146.62 | P/E TTM: ~41x | P/E fwd: ~26x | Div Yield: ~0.5% | Market Cap: ~$1.06 trillion USD
What is Eli Lilly?
One of the largest and oldest drug companies in the world, founded in Indianapolis in 1876 by Colonel Eli Lilly. In November 2025 it became the first healthcare company in history to be worth one trillion dollars. Its engine today is the family of GLP-1 / incretin medicines: they copy a natural hormone that reduces appetite and controls blood sugar. CEO David A. Ricks (since January 2017). ~50,000 employees. In 2026 it turns 150.
The products (Q1 2026)
| Product | For what | Q1 2026 sales |
|---|---|---|
| Mounjaro (tirzepatide) | Type 2 diabetes | $8.66 billion (+125%) |
| Zepbound (tirzepatide) | Obesity / sleep apnea | $4.16 billion U.S. (+80%) |
| Foundayo (orforglipron) | First GLP-1 pill for losing weight | Just launched (approved Apr 1, 2026) |
| Kisunla (donanemab) | Early Alzheimer's | $124 million (ramping) |
| Verzenio | HR+ breast cancer | ~$5.5 billion/year |
| Jardiance, Taltz, Ebglyss… | Diabetes/heart, psoriasis, eczema | Multi-billion-dollar franchises |
Mounjaro + Zepbound = $12.8 billion in a single quarter (~$51 billion annualized). Lilly has ~60% of the world market for GLP-1.
Latest quarter (Q1 2026, reported Apr 30, 2026)
| Metric | Q1 2026 |
|---|---|
| Revenue | $19.8 billion (+56%) (volume +65%, price −13%) |
| Adjusted EPS (non-GAAP) | $8.55 (+156%) |
| GAAP EPS | $8.26 (+170%) |
2026 guidance raised: revenue $82-85 billion (before $80-83), adjusted EPS $35.50-37.00. Implies ~+40% growth vs 2025. Next report: August 5, 2026 (consensus ~$20.5 billion / EPS $7.74).
The story: the GLP-1 wave
- Obesity is the biggest drug market ever opened: hundreds of millions of potential patients in the world.
- Foundayo (the pill) is the key catalyst: approved on April 1, 2026, it is the first GLP-1 pill for losing weight; up to ~12% weight loss in studies, with no food or water restrictions. A pill is cheaper to make and reaches far more people than an injection.
- The rival stumbled: Novo Nordisk's CagriSema lost the head-to-head comparison against Zepbound (20% vs 24% weight loss); Novo projects that its obesity sales will shrink in 2026.
- The next ace up the sleeve: retatrutide, in the final phase, achieved in May 2026 something never seen — 30%+ average weight loss (~38 kilos) in a large study (TRIUMPH-1), the most of any medicine; on July 23 it cleared doubts about heart safety.
Dividend (small but growing)
- $1.73 per share per quarter = $6.92 a year = ~0.5% at $1,146.62. It is low because the stock shot up, not because the payment is weak.
- 12 years in a row raising it (the last increase +15%).
Anchor Fact
On November 21, 2025, Eli Lilly became the first healthcare company in history to be worth one trillion dollars. A single quarter of its weight-loss medicines ($12.8 billion) brings in more than entire drug companies — and its next medicine, retatrutide, just achieved 30% average weight loss in a large study, something never seen before.
Top 5 Risks
- Valuation / expectations — ~41x historical earnings, ~$1.06 trillion in value; average target (~$1,236) only ~8% higher; the August 5 report is a demanding exam
- Competition — Novo Nordisk (price war: −13% in real prices), and Amgen/Viking arriving ~2027
- Government price pressure — MFN deal (~$245/month Medicare), mandatory Medicare negotiation
- Patents — Trulicity (~2027), Jardiance (~2028), Verzenio (~2029) erode this decade; constant acquisitions to replace revenue (AtaiBeckley, up to $3.8 billion, Jul 2026)
- Concentration in tirzepatide — a safety/manufacturing/regulatory problem in that family would hit very hard
Analyst consensus
- Rating: Buy / Overweight (~38 analysts)
- Average target: ~$1,236 (~+8% from $1,146.62); S&P ~$1,270
- Recent raises (Jul 2026): UBS $1,425, JPMorgan $1,400, Morgan Stanley $1,347
Thesis in one line
The undisputed leader of the biggest wave in modern medicine —the weight-loss medicines—, with the market's first pill, ~60% share and +40% growth, bought ~8% below its all-time high.
Research date: 23 Jul 2026 | Next review: Jan 2027
This is not financial advice.
This is not financial advice. Consult a certified financial advisor.
The author may hold positions in the securities discussed.
Past performance does not guarantee future results.